Please assess the completion status of the following clinical trial:

Trial Title: Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
(main) Inclusion Criteria:~* age 18 - 75 years at screening~* ability to give written consent, informed written consent~* negative pregnancy test at screening~* therapy-refractory Myasthenia Gravis (generalized) or Systemic Lupus Erythematosus or Rheumatoid Arthritis~(main) Exclusion Criteria:~* Belimumab therapy within the last 6 months~* B-cell-depletion therapy within the last 9 months~* heart or kidney insufficiency~* known intolerability to Bortezomib~* participation in another interventional trial within the last 3 months~* liver cirrhosis~* preexistent sensory or motor polyneuropathy ≥ degree 2 (NCI CTC AE criteria), within 14 days before screening~* hints on clinically apparent herpes zoster reactivation~* active systemic infection, or viral infection (CMV, EBV) within last 6 month before screening~* serologically active hepatitis B and /or C, known HIV infection~* tumor disease currently or within last 5 years~* clinically relevant liver, kidney or bone marrow function disorder~* pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bortezomib (Velcade) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).